Healthcare Sales & Marketing Network News: ATHENA study

Searching News Database: ATHENA study

HSMN NewsFeed - 30 Nov 2009
sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 2 Jul 2009
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 11 Feb 2009
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 3 Sep 2008
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 8 Aug 2008
Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 15 May 2008
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.